drugset / Trial / NCT01562834

Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients

NCT01562834

Phase 4 Completed 22 enrolled Novo Nordisk A/S
RandomizedCrossoverDouble-blindTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to assess the effect of somatropin (Norditropin®) replacement therapy on the left ventricular mass of adult patients with a growth hormone deficiency.

Timeline

Start
1998-10-21
Primary completion
2002-12-01
Completion
2002-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 0.5 iu Subcutaneous

Indications

No indication recorded.